Novavax’s Nuvaxovid has authorised its vaccine in more than 40 markets worldwide. Credit: rarrarorro via Shutterstock.

US-based received its first full marketing authorisation for its Covid-19 vaccine Nuvaxovid (NVX-CoV2373) in the EU.

Nuvaxovid is now fully authorised as a primary series vaccine for general Covid-19 prevention for individuals aged 12 years and older and as a booster dose in adults aged 18 years and older.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The approval follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in May 2023, surrounding the vaccine鈥檚 full approval.

The full authorisation comes a few years after the European Medicines Agency (EMA) granted the prophylactic a conditional marketing authorisation, in December 2021. At the time, Nuvaxovid was the fifth vaccine recommended for Covid-19 prevention in the EU. has authorised its vaccine in more than 40 markets worldwide.

Nuvaxovid is a novel Matrix-M adjuvant protein-based vaccine that has received a US Food and Drug Administration (FDA) emergency use authorisation but has not yet received full US approval.

In a 6 July press release, Novavax鈥檚 president and CEO John C Jacobs said: 鈥淚n addition to the EU, we are preparing to file for full approval in the US as well as other markets and are committed to ensuring protein-based options are available worldwide. Vaccine choice remains an integral part of public health measures.”

The immunisation is developed by producing copies of the spike protein on the SARS-CoV-2 virus that causes the disease. As a first booster, the vaccine must be given at least six months after a patient receives their first vaccination with an approved Covid-19 vaccine.

The European Commission鈥檚 decision was based on results from the (NCT04611802) that investigated the safety, immunogenicity, and efficacy of Nuvaxovid. demonstrated that the vaccine had an efficacy of 79.5% in preventing the disease and 82% specifically for preventing the Delta variant. According to GlobalData, the company is also studying the vaccine in nine ongoing clinical trials to evaluate its use in infants (NCT04611802), pregnant women (NCT04705116) and more patient groups.

GlobalData is the parent company of Pharmaceutical Technology.

During the pandemic, the European Medicines Agency (EMA) granted the prophylactic a conditional marketing authorisation, making it the fifth vaccine recommended for Covid-19 prevention in the EU. Novavax has authorised its vaccine in more than 40 markets globally.